tially prevented by a simultaneous infusion of a The roles of nitric oxide derived from either the liver-selective NO donor. Inhibition of PMN accuconstitutive endothelial NO synthase (eNOS or mulation using an anti-ICAM-1 antibody or by PMN NOS3) or the inducible NOS (iNOS or NOS2) in hedepletion using vinblastine pretreatment, however, patic injury during endotoxemia remain controverdid not reverse the increased necrosis with NAME sial. To investigate this further, rats received a boinfusion during endotoxemia. In contrast to the aslus of lipopolysaccharide (LPS) following implantasessment for necrosis, increased apoptosis was obtion of osmotic pumps containing one of two served in the livers of LPS-treated rats receiving nonselective NOS inhibitors (NMA or NAME), one infusions of either NAME or NIL, but not with LPS of two inducible NOS inhibitors (NIL or AG), or saalone. These data indicate that NO produced by line. The inhibitors were infused continuously into eNOS may be adequate to prevent necrosis by a the liver via the portal vein. Treatment of LPS-inmechanism independent of PMN, while induced NO jected rats with NMA and NAME resulted in 106 and appears to prevent apoptosis. ᭧ 1997 Academic Press 227% increases, respectively, in circulating hepatic Key Words: Nitric oxide; NOS inhibitors; liver; neenzyme levels compared to LPS-treated control crosis; apoptosis; neutrophil; adhesion molecule. rats. In contrast, infusion of the iNOS-selective inhibitors had no effect on the LPS-induced hepatic necrosis. In rats receiving NAME, LPS induced Administration of endotoxin (lipopolysaccharide, greater neutrophil infiltration and ICAM-1 expres-
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systemic inflammatory response and organ injury this study in which either nonselective NOS inhibitors (N G -nitro-L-arginine methyl ester [NAME] or characteristic of sepsis. Hepatic responses induced by experimental endotoxemia include the activation N G -monomethyl-L-arginine [NMA]) or inhibitors with some selectivity toward iNOS (L-N 6 -(1-iminoof reticuloendothelial cells followed by degenerative changes in hepatocytes (1, 2). Cytotoxicity has also ethyl)lysine [NIL] or aminoguanidine [AG] (27) (28) (29) ) were continuously infused directly into the portal been described following exposure of hepatocytes to endotoxin in vitro (3) and nonparenchymal-hepatovein of rats treated with LPS. We examined not only hepatic necrosis but also apoptosis, and report the cyte cocultures (4). The mechanisms of hepatocellular toxicity in endotoxemia appear to involve cytonovel observation that nonselective inhibitors increase both hepatic necrosis and apoptosis, whereas kines such as tumor necrosis factor a (TNF-a) (5) and toxic radicals (6). Recent work has focused on iNOS-selective inhibitors promote only apoptosis. Furthermore, nonselective inhibitors increased nitric oxide as a pivotal cellular mediator in the liver during endotoxemia. Whereas some studies have ICAM-1 expression and PMN accumulation but iNOS-selective inhibitors did not. However, the insuggested that reactive nitrogen intermediates induce tissue injury, including in hepatocytes (4, 7, 8) , creased hepatic necrosis with nonselective NOS inhibitors was not dependent on PMN accumulation. others support the concept that NO plays a hepatoprotective role (9) (10) (11) (12) (13) (14) . We have suggested that the These results suggest specific and separate actions for NO produced by eNOS and iNOS in the liver in end result of NO formation may be dependent on the rate of NO synthesis, the cellular source of the NO, endotoxemia. the quantity and species of other radicals that are produced, and the antioxidant status of the liver MATERIALS AND METHODS (10, 11, 15) . Materials The quantity of NO synthesized in a tissue and the temporal pattern of production are dependent on NMA was from CHEM-BIOCHEM Research Inc. the types of NOS isoforms expressed. Three NOS (Salt Lake City, UT). AG was from Aldrich Chemiisoforms are known to exist and include the neuronal cal Co. (Milwaukee, WI). NIL was provided by P. NOS (nNOS or NOS1), the inducible or inflammaDavies of Merck Research Laboratories (Rahway, tory NOS (iNOS or NOS2), and the endothelial NOS NJ). Alzet osmotic pumps, Model 2001D, were from (eNOS or NOS3) (reviewed in 16, 17 (9, We have previously reported the design, synthe-10, 25) and inhibitors with some selectivity toward sis, and specificity of a compound, O 2 -vinyl 1-(pyriNOS have been reported to reduce damage (26), it rolidin-1-y1)diazen-1-ium-1,2-diolate (V-PYRRO/ is possible that the consequence of NO production NO), which concentrates NO release in the liver will be determined by the enzymatic source. Howin vivo (31) . ever, in these previous studies the inhibitors were administered systemically and as a bolus, raising
Experimental Protocol concerns about the effective delivery of the inhibitor to the liver. To establish the consequences of eNOS Experimental procedures were approved by the Institutional Animal Care and Use Committee, Unior iNOS inhibition within the liver, we undertook 406 OU ET AL. versity of Pittsburgh. Male Sprague-Dawley rats tered intravenously 30 min before the LPS injection. Neutropenia was induced by a single dose injection (250-300 g, from Harlan Sprague-Dawley, Madison WI) were fasted overnight prior to the initiation of vinblastine at 0.5 mg/kg, 5 days prior to pump placement and injection of LPS. Total white blood of the experiments but allowed free access to water.
Prior to the injection of LPS, Alzet osmotic pumps cells were counted using a Coulters Microdiff 16. PMN were quantified by counting at 4001 magnifiwere implanted for the continuous infusion of NOS inhibitors, V-PYRRO/NO (NO donor), or vehicle concation (Quik Diff) in a blinded fashion. trols. For NOS inhibitor infusion, PE-10 catheter tubing was inserted into the left gastric vein for diImmunohistochemistry rect portal vein infusion with the pump positioned For immunohistochemical analysis, the liver was in the peritoneal cavity. In some rats a second pump perfused with 30 ml saline, embedded in ornithine containing V-PYRRO/NO was implanted subcutanecarbamoyltransferase (OCT), and frozen in liquid niously on the back of the animal with the catheter trogen. Liver sections were stained using the aviinserted into the jugular vein. Animals were anesdin-biotin-complex method (32). Briefly, frozen thetized with inhaled isoflurane for the procedure, specimens were sectioned with a cryostat, air-dried the PE-10 catheter tubing was inserted into the vein overnight, fixed in acetone for 10 min, air-dried for through a venotomy, and the vein was ligated 15 min, rehydrated in 1% bovine albumin-phosaround the catheter. The catheter was flushed with phate-buffered saline for 10 min, and then incubated the same solution that was used to fill the pump and with the primary antibody (1:200 RP3, an anti-rat then connected to the pump. All pumps were placed PMN monoclonal antibody (33), or anti-ICAM-1) for in saline solution at 37ЊC for 4 h before use so that 1 h. The biotinylated secondary antibody and avithe flow into the vein would start immediately after din-biotin complex (Vector Lab, Burlingame, CA) implantation. LPS (12 mg/kg) or saline was injected were applied for 30 and 45 min, respectively. A perintravenously after the completion of pump placeoxidase chromogen kit (Biomeda Co., Foster City ment, and no other pharmacologic reagents were CA) was used to visualize antibody binding. The subgiven during the infusion period until the animals stitution of the isotype-matched control antibody for were anesthetized again with isoflurane just prior the primary antibody was used as a negative control. to sacrifice for plasma and liver tissue isolation, 16 Neutrophils were identified by RP3-positive staining h following the injection of the LPS. AG was delivand morphology, and the average number was deterered at a dose of 125 mmol/kg/h; NMA was delivered mined by counting 40 high-power fields at 4001 at 20.8 mmol/kg/h; NAME at 6.9 mmol/kg/h; NIL at magnification in a blinded fashion. Only those neu-20.8 mmol/kg/h; NAME / NIL at 3.4 / 10.4 mmol/ trophils that were present within sinusoids or exkg/h, respectively; and V-PYRRO/NO at 1.1 mmol.
travasated into the tissue, and not neutrophils presThe doses of the NOS inhibitors were selected by ent in large hepatic vessels, were counted. first establishing the lethal dose of NAME (10.4 mmol/kg/h) in rats given LPS and then reducing the dose to a sublethal amount. The doses of the other DNA Fragment Assay NOS inhibitors were then calculated based on the published IC 50 values for these compounds against Enriched, low-molecular-weight DNA from whole liver tissue was isolated and extracted according to iNOS and eNOS relative to NAME (27) (28) (29) . The dose of V-PYRRO/NO was based on our published data modifications of the methods of Wyllie (34) as well as Hughes and Gorospe (35) . Whole frozen liver tisshowing hepatic NO release without systemic hypotension (31) .
sue was homogenized in ice-cold lysis buffer (5 mM Tris, 20 mM EDTA, 0.5% Triton X-100, pH 8.0). Following the addition of diethyl pyrocarbonate (DEPC, Administration of Antibodies and Induction of final concentration Å 0.2% v/v) to inhibit endogenous Neutropenia nuclease activity, homogenates were incubated on ice for 90 min with occasional mixing. The homogeThe anti-rat ICAM-1 IgG antibody (2 mg/kg) or isotype-matched antibody (control) was adminisnate was then centrifuged at 27,000g for 20 min to
separate fragmented DNA and subjected to proteinml sample, vortexed for 30 s, and centrifuged to pellet the protein. Total NO 0 2 / NO 0 3 was determined using ase K digestion (0.5 mg/ml, 1 h at 37ЊC) followed by repeated phenol:chloroform extraction. Nucleic acids an automated HPLC system based on the Griess reaction, in which NO 0 2 is first converted to NO 0 3 using were precipitated with 100% ethanol at 020ЊC, collected by centrifugation at 15,000g, and subjected to copper-coated cadmium, as described (36) . ribonuclease A (2.5 mg/ml) treatment. Samples were extracted, precipitated as above, and dried, and nuBiochemical Analysis cleic acid pellets were resuspended in TE buffer (10 Activities of alanine aminotransferase (ALT) and mM Tris, 1 mM EDTA, pH 8.0). The concentration aspartate aminotransferase (AST) in plasma were and purity of DNA were estimated spectrophotometdetermined with a chemistry autoanalyzer (Bayer, rically by the ratio of absorbencies at 260 and 280
Pittsburgh, PA). nm. Samples (Ç50 mg DNA) were mixed with gel loading buffer (0.05% w/v bromophenol blue, 40% w/ v sucrose, 0.1 M EDTA, pH 8.0) and electrophoresed Statistical Analysis on 2% agarose gels at 50 V in TAE buffer (40 mM Results are expressed as means { SE with the Tris, 5 mM sodium acetate, 1 mM EDTA, pH 7.6).
number of different experiments given in the figure Gels were stained with ethidium bromide and visulegends. Statistical significance between groups was alized by ultraviolet transillumination. A doubledetermined using ANOVA, with significance estabstranded 123-bp DNA ladder served as a standard.
lished at P õ 0.05.
Light Microscopic Detection of Apoptosis

RESULTS
Cryosections of fixed, frozen livers were cut, mounted on slides, and labeled using the TUNEL We examined the effects of nonselective or selecassay. This assay specifically detects laddered DNA tive NOS inhibition 16 h following the injection of by terminal tailing of DNA with fluorescently tagged LPS. This time point was chosen based on previous bases. DNA strand breaks were directly labeled by data showing that iNOS expression peaked between incubating sections with 10 M fluorescein-12-dUTP 12 and 16 h (37) and preliminary data showing that and 200 U terminal deoxynucleotidyltransferase/ml in both injury and neutrophil infiltration peaked at this reaction buffer. Cobalt was added to enhance labeling time point (data not shown). LPS injection has been of protruding, recessed, and blunt DNA breaks conshown to transiently elevate circulating NO 0 2 / taining a free 3-OH. After 45 min at 37ЊC, the reaction NO 0 3 levels in rats (18). Even though plasma NO 0 2 was terminated by washing with PBS and the speci-/ NO 0 3 would not be expected to selectively measure men was counterstained with Hoechst 33258, 2 mg/ hepatic NO production, acute changes in levels can ml for 3 min. This stain specifically stains DNA and be used as an estimate of increased systemic NO allows all nuclei in the section, or the entire section, production. In agreement with previous studies, we to be examined. The cells were then mounted in Gelvafound that intravenous administration of LPS retol and observed using a Nikon FXL photomicroscope.
sulted in an increase in plasma levels of NO 0 2 / Random images using a 601 objective were collected NO 0 3 from a baseline of 9.3 { 4.5 to 367.2 { 47.6 mM using a 3 Chip Sony color camera. The apoptotic nuclei ( Fig. 1 ) at 16 h in animals implanted with Alzet in each field were counted and the types of apoptotic pumps containing only saline. Portal vein infusion cells were classified.
of NIL, AG, NMA, NAME, or NIL / NAME reduced the LPS-induced increases in plasma NO tively, compared to the LPS-treated animals with pumps containing saline (Fig. 1) . Thus, all the inhibFor the NO 0 2 / NO 0 3 assay, plasma was collected and stored at 080ЊC. Samples were thawed and deproitors exhibited significant activity toward the LPSinduced NO production. teinized by the addition of 400 ml 0.5 N sodium hydroxide and 400 ml 10% zinc sulfate solution to each 200 LPS injection induced hepatocellular necrosis as 408 OU ET AL.
trated in the liver because this prodrug is metabolized to NO preferentially in hepatocytes (31) . Infusion of V-PYRRO/NO in LPS-treated rats in the absence of NAME had no effect on AST levels, but when given with NAME, the donor attenuated the increase in liver damage, as measured by a reduction in plasma AST levels (Fig. 3) . Thus, the NAME-induced increase in injury appears to be due, at least in part, to an inhibition of NO synthesis. It has been proposed that NO protects the liver from damage by blocking neutrophil infiltration (38, 39) . To assess the effects of NOS inhibition on PMN infiltration, the number of infiltrating neutrophils at 16 h following LPS treatment was determined. As shown in Fig. 4 , LPS injection in the absence of NOS inhibitors resulted in a 4.25-fold increase in neutrophil infiltration over controls (saline-containing Increased ICAM-1 expression occurs in the liver following endotoxemia (40) and contributes to neuindicated by a 1.8-fold increase in plasma ALT and trophil-mediated injury in liver ischemia/reperfu-AST levels. Constant portal vein infusion of AG and sion injury (41) . Therefore, we examined the level NIL did not alter the LPS-induced increases in of ICAM-1 protein expression in liver sections by plasma enzyme levels. In contrast, infusion of NMA, immunohistochemistry using an anti-ICAM-1 mono-NAME, and NIL / NAME all caused significant inclonal antibody. Faint constitutive ICAM-1 protein creases in LPS-induced liver damage ( Fig. 2A) . Heexpression was detected on surfaces of the sinusoid matoxylin-and eosin-stained liver sections conendothelial cells in rats that received pumps with firmed the presence of hepatocellular necrosis in the saline (Fig. 5A) , which was not different from livers NAME-treated rats but not NIL-treated rats during studied from control rats without pumps (not endotoxemia (data not shown). Infusion of the NOS shown). Infusion of NAME or NIL without LPS did inhibitors alone did not result in detectable liver not cause a detectable change in ICAM-1 expression damage (Fig. 2B) . Thus, in LPS-treated animals, (Figs. 5B and 5C). ICAM-1 expression was increased nonselective inhibitors resulted in hepatocellular neafter LPS injection in rats with an intraportal infucrosis but iNOS-selective inhibitors did not. Furthersion of saline (Fig. 5D ). Portal vein infusion of NAME more, the infusion of NIL with NAME did not reduce following LPS injection resulted in an even greater the NAME-induced injury.
increase in the LPS-induced increase in ICAM-1 exTo determine if the increase in injury induced by pression (Fig. 5E ). In contrast, infusion of NIL had NAME could be reversed by providing an exogenous no effect on LPS-induced changes in ICAM-1 expressource of NO, rats with portal vein NAME infusion sion levels (Fig. 5F ). The combination of NIL with received a simultaneous infusion of V-PYRRO/NO. NAME appeared identical to using only NAME with The V-PYRRO/NO was infused constantly into the jugular vein; however, the release of NO is concen-LPS, whereas the infusion of V-PYRRO/NO with Copyright ᭧ 1997 by Academic Press. All rights of reproduction in any form reserved.
DIFFERENTIAL EFFECTS OF iNOS AND eNOS INHIBITION IN LIVER
FIG. 2. NMA and NAME aggravate hepatocellular necrosis in LPS-treated animals. Rats were injected with LPS (A) or saline (B)
following implantation with osmotic pumps for portal vein infusion of either the NOS inhibitors indicated or saline. Plasma AST and ALT levels were determined 16 h after LPS injection. Data are the mean { SE from seven animals per group (*P õ 0.03 vs saline / LPS).
FIG. 3.
Exogenous NO partially prevents the NAME- induced  FIG. 4 . Effect of NOS inhibition on neutrophil accumulation in the liver. Rats received a single dose of LPS or saline intraveliver injury in LPS-treated rats. Rats were injected with LPS intravenously following implantation of two pumps-one osmotic nously following implantation of osmotic pumps containing saline, NIL, NAME, or NIL / NAME for portal infusion. Some of pump containing NAME or saline with the catheter positioned in the portal vein, and another pump containing V-PYRRO/NO or the rats with NAME pumps received a second pump containing V-PYRRO/NO for simultaneous jugular vein infusion. Neutrosaline with the catheter positioned in the jugular vein. Blood samples were taken just before sacrificing the animals, 16 h after phils in liver tissue were stained and counted as described under Materials and Methods. Data represent the mean { SE for six the LPS injection. Data are the mean { SE from six animals per group (*P õ 0.05 vs jugular saline, portal NAME).
animals per group (*P õ 0.03 vs saline / LPS). 
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FIG. 6. Effect of anti-ICAM-1 antibody or neutrophil depletion on circulating and liver neutrophil counts. (A) Liver neutrophil counts
were determined by immunohistochemistry using RP3, an anti-rat neutrophil monoclonal antibody, 16 h following injection with saline or LPS. Some rats were pretreated with anti-ICAM-1 antibody or isotype-matched control antibody while other rats were pretreated with vinblastine 5 days to induce neutropenia. Neutrophils were counted in 40 high-power fields in a blinded fashion (*P õ 0.04 vs LPS-NAME). (B) Circulating neutrophil counts were obtained from the same animals described under (A) at time of sacrifice (n Å 6, mean { SE) (*P õ 0.001 vs LPS / NAME).
NAME attenuated the increase in ICAM-1 exprescell types (42-44) but inhibits apoptosis in other cell types (45-47), including hepatocytes (31). To detersion in LPS-treated rats (not shown).
We next carried out experiments to determine if mine if NOS inhibition altered the level of apoptosis in the liver following LPS treatment, DNA isolated the increase in PMN accumulation caused by NAME infusion during endotoxemia contributed to the infrom liver was analyzed for fragmentation characteristic of apoptosis. In the absence of LPS, intraporcrease in hepatocellular damage. Injection of a blocking anti-ICAM-1 antibody but not an isotype tal infusion of saline, NAME, NIL, NIL / NAME, or the NO donor V-PYRRO/NO did not result in decontrol prevented the NAME-induced increase in PMN accumulation in the liver (Fig. 6A ), but did not tectable DNA fragmentation (Fig. 8) . Injection of LPS with portal saline infusion also was not associreduce circulating PMN counts (Fig. 6B) . We also inhibited PMN accumulation by inducing neutroated with detectable apoptosis. In contrast, infusion of any of the NOS inhibitors with LPS resulted in penia using vinblastine pretreatment. As shown in Fig. 6B , a single injection of vinblastine 5 days prior the appearance of DNA fragmentation, indicating increased levels of apoptosis in these livers. Coinfuto LPS injection resulted in a 99.3% drop in circulating PMN counts. This treatment also completely presion of V-PYRRO/NO with NAME prevented the appearance of DNA fragmentation. Thus, nonspevented the NAME-induced increase in PMN infiltration in the liver. However, no change in liver damcific NOS inhibition increased both necrosis and apoptosis, whereas infusion of an iNOS-specific inage was detected with either anti-ICAM-1 antibody or vinblastine pretreatment (Fig. 7) . Thus, the hibitor with LPS increased only apoptosis.
To identify the distribution of apoptotic cells NAME-induced hepatocellular injury in the LPStreated animals is associated with, but occurs indewithin the liver of LPS-treated rat infused with NIL, liver sections were subjected to the TUNEL assay. pendent of, increased PMN accumulation.
Increases in circulating hepatic enzyme levels is No apoptosis was detectable in hepatocytes from the animals treated with LPS or NIL alone (not shown). a measure of hepatocellular necrosis but may not detect cell death due to apoptosis because cells unIn LPS-treated animals infused with NIL, apoptosis was observed predominantly in endothelial cells and dergoing apoptosis do not release their contents. NO exposure has been shown to cause apoptosis in some other sinusoidal cells, though it could also be de-412 OU ET AL.
neutrophil infiltration. The failure of the iNOS-selective inhibitors to mimic the effects of the nonselective inhibitors argues that the doses of NIL and AG that we used did not significantly inhibit eNOS. NIL infusion was, however, associated with the appearance of apoptosis in the livers of LPS-treated animals. Taken together, these data suggest that NO derived from eNOS functions in protecting the liver from inflammation-induced necrosis, whereas NO produced by iNOS or a combination of iNOS and eNOS functions to prevent apoptosis. Our results are consistent with previous reports examining the effect of nonselective NOS inhibitors on liver injury in rodent endotoxemia (9, 10, 25) but inconsistent with a study which examined selective   FIG. 7 . Effect of neutrophil inhibition on NAME-induced liver iNOS inhibitors (26). All of these previous studies injury in LPS-treated rats. Plasma AST and ALT levels were examined the effect of bolus injection of the inhibidetermined 16 h following the injection of LPS. All animals underwent placement of an osmotic pump for portal vein infusion of NAME just prior to LPS treatment. Some rats were pretreated with anti-ICAM-1 antibody or an isotype-matched control antibody while other animals were pretreated with vinblastine 5 days prior in order to induce neutropenia (see Fig. 6 ) (n Å 6, mean { SE). tected in hepatocytes (Fig. 9) . In this group, the proportion of cells undergoing apoptosis detectable by TUNEL at 16 h was between 1 and 3% of the total cell population.
DISCUSSION
Although it is well-established that NO production increases in the liver in acute inflammatory conditions such as endotoxemia (18), the consequences and functions of local hepatic sources of NO remain controversial. This study was undertaken to examine the effects of the direct and constant intraportal infusion of NOS inhibitors with differing potencies against eNOS (NOS3) and iNOS (NOS2). We show here that nonselective inhibitors increase hepatic necrosis following LPS injection. This increased necrosis was associated with an increase in neutrophil infiltration into the liver   FIG. 8 . Detection of apoptosis in LPS-treated rats. Rats received a single dose of LPS or saline intravenously following implantaand hepatic ICAM-1 expression; however, the injury tion with osmotic pumps containing saline, NIL, NAME, or NIL was independent of the neutrophil accumulation. In / NAME for portal vein infusion. Some of the NAME rats received clear contrast to the nonselective inhibitors, inhibitors a second pump containing V-PYRRO/NO for simultaneous jugular with 30-to 100-fold selectivity toward iNOS compared infusion. DNA fragmentation was assayed 16 h after LPS injecto eNOS (NIL and AG) (27) (28) (29) caused no change in tors in models of endotoxin-induced liver injury. In to inhibition of NO production specifically in the liver. This possibility seems unlikely because we our own previous work, we showed that bolus injection of NMA at the time of LPS injection in a model would expect that even though we infused inhibitors directly into the liver, it is probable that enough of of endotoxin hypersensitivity significantly increased liver damage (9) through mechanisms which appear the infused material escaped metabolism in the liver to have systemic actions. This is supported by the to involve oxygen radical production and platelet deposition (10) . NO was shown to act in concert with near-complete inhibition of elevations in plasma NO 0 2 / NO 0 3 levels by NIL and AG infusion and prostacyclin to attenuate liver damage (11) . We also showed that bolus injection of sufficient doses of based on the assumption that extrahepatic sources of NO also contribute to elevations in plasma NO x NMA 6 h after LPS infusion caused a modest increase in liver injury (25). Others have since verified levels. Second, differences in timing of the administration of the inhibitors may be important. Finally, our observations using nonselective NOS inhibitors (48) . In contrast to the studies using nonselective some isothioureas have been shown to block not only iNOS enzyme activity but also iNOS expression (49), inhibitors, Szabo et al. (26) recently reported that bolus administration of an isothiourea, which exhiband therefore this class of compounds could have salutary actions unrelated to iNOS inhibition. its selectivity toward iNOS, prevents liver damage in a model of rat endotoxemia. To overcome any unThe increase in hepatocellular necrosis with inhibitors effective toward both eNOS and iNOS but not toward effects of bolus infusion and to assure that the inhibitors reached the liver in adequate conceninhibitors selective for iNOS suggests that NO derived from eNOS is critical to preventing hepatoceltrations to inhibit NOS activity, we devised a method that delivers a constant infusion of NOS inlular necrosis. Our results also raise the possibility that eNOS regulates ICAM-1 expression in the inhibitors directly into the portal vein by cannulating the left gastric vein with a catheter connected to an flamed liver. The observation that anti-ICAM antibodies block neutrophil accumulation also suggests Alzet osmotic pump. Our results confirm the results of previous studies showing increased necrosis with but does not prove that the increased ICAM-1 expression promotes neutrophil accumulation associnonselective NOS inhibition but failed to demonstrate a protective effect with selective iNOS inhibiated with NOS inhibition. The capacity of the liverspecific NO donor to reduce the damage, ICAM-1 tors. Several potential explanations exist for the difference between our study and the previous study expression levels (data not shown), and neutrophil influx points to the importance of NO in all three using isothiourea. First, the reported benefit from iNOS inhibition on hepatic necrosis could be due to changes. Even though activated neutrophils have been shown to kill hepatocytes (50), the failure to improved systemic hemodynamic effects and not due link neutrophil accumulation with necrosis indicates ulus for the apoptosis, although TNF-a is a likely candidate (5). Furthermore, the increase in that the enhanced hepatocellular injury is not mediated by neutrophils. This conclusion is additionally apoptosis was seen with all the NOS inhibitors, whereas the increase in necrosis was detected only supported by the experiments using vinblastine, which assures that PMN were depleted throughout with inhibitors which effectively blocked eNOS. Because both NMA and NAME have activity toward the experimental period. The cause of the hepatocellular necrosis is unclear, but may include the unopiNOS, it cannot be determined if the increase in apoptosis with these inhibitors was due to iNOS or posed action of oxygen radicals or alterations in liver perfusion. It is likely that the combined inhibition eNOS inhibition. Nonetheless, these studies reveal another potential mechanism of protection for NO of iNOS and eNOS causes severe disturbances in the hepatic microcirculation through an increase in in the liver as an antiapoptotic agent.
It is important to point out that the doses and intrahepatic resistance. Using an isolated perfused liver system, we have shown that nonselective NOS route of administration of the inhibitors used in these experiments were chosen to permit the study inhibitors reverse the hyporeactivity to phenylephrine caused by LPS pretreatment (51).
of the actions of NO in the liver in endotoxemia and not to determine the efficacy of NOS inhibitors to NAME infusion alone has been shown to increase PMN infiltration into the mesentery (52, 53) through treat clinical septic shock. Significantly lower doses of NMA have been used to reverse hypotension witha process in which the inhibition of NO synthesis causes mast cell degranulation (54). Inhibition of enout leading to hepatocellular injury based on plasma enzyme levels (59, 60). dothelial NO production results in increased ICAM-1 expression and neutrophil adhesion to endothelial monolayers in vitro (55), whereas both NO (56) and
